# Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

> **NCT01096602** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 63 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- AML

## Interventions

- **BIOLOGICAL:** DC AML Vaccine

## Key facts

- **NCT ID:** NCT01096602
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2023-12
- **Final completion:** 2024-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096602, "Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01096602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*